During the past decade, Groupe Hospitalier Mutualiste de Grenoble conducted 46 clinical trials. In the 10-year time frame, 46 clinical trials started and 1 clinical trials were completed, i.e. on average, 2.2% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 1 clinical trials were completed. i.e. 4.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Groupe Hospitalier Mutualiste de Grenoble" #1 sponsor was "ARCAGY/ GINECO GROUP" with 7 trials, followed by "Groupe Hospitalier Mutualiste de Grenoble" with 7 trials sponsored, "University Hospital, Grenoble" with 6 trials sponsored, "Centre Leon Berard" with 4 trials sponsored and "Rennes University Hospital" with 4 trials sponsored. Other sponsors include 21 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Groupe Hospitalier Mutualiste de Grenoble" #1 collaborator was "Floralis" with 3 trials as a collaborator, "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 2 trials as a collaborator, "Fondation de l'Avenir" with 2 trials as a collaborator, "TIMC-IMAG" with 2 trials as a collaborator and "AG2R La Mondiale" with 1 trials as a collaborator. Other collaborators include 29 different institutions and companies that were collaborators in the rest 39 trials.

According to Clinical.Site data, the most researched conditions in "Groupe Hospitalier Mutualiste de Grenoble" are "Ovarian Cancer" (5 trials), "Acute Coronary Syndrome" (4 trials), "Breast Cancer" (3 trials), "Coronary Artery Disease" (3 trials) and "Metastatic Breast Cancer" (2 trials). Many other conditions were trialed in "Groupe Hospitalier Mutualiste de Grenoble" in a lesser frequency.

Most popular intervention types in "Groupe Hospitalier Mutualiste de Grenoble" are "Drug" (19 trials), "Other" (15 trials), "Device" (12 trials), "Procedure" (5 trials) and "Behavioral" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Chemotherapy" (2 trials), "Niraparib" (2 trials), "Olaparib" (2 trials) and "5-fluoro-uracil/oxaliplatin/leucovorin (folfox)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Groupe Hospitalier Mutualiste de Grenoble" are 37 trials for "All" genders, 15 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Groupe Hospitalier Mutualiste de Grenoble". 2 are not yet recruiting, 10 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Groupe Hospitalier Mutualiste de Grenoble, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Groupe Hospitalier Mutualiste de Grenoble, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 20 trials that are defined as “Not Applicable".

Groupe Hospitalier Mutualiste de Grenoble has several departments that took part in Clinical trials: "Institut Daniel Hollard" - 32 trials